EMA Authorised: Jorveza (Budesonide) — Dr. Falk Pharma GmbH

View source ↗

Summary

EMA authorised Jorveza (budesonide) by Dr. Falk Pharma GmbH for eosinophilic esophagitis; the approval is designated orphan medicine with accelerated assessment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Jorveza (budesonide)

Snippet

Status: Authorised. Therapeutic area: Esophageal Diseases. MAH: Dr. Falk Pharma GmbH. Decision date: 08/04/2026. Orphan medicine. Accelerated assessment